The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.La présente invention concerne le composé KC-8, cest-à-dire lacide N-1-[3-(oxycodone-6-ènol-carbonyl-méthyl-amino)-2,2-diméthyl-propylamine]-arginine-glycine-malonique, ou ses sels, solvates et hydrates acceptables. Linvention concerne également des compositions et leurs procédés dutilisation, les compositions contenant un promédicament, le composé KC-8, qui permet une libération contrôlée doxycodone. Ces compositions peuvent contenir éventuellement un inhibiteur de trypsine qui interagit avec lenzyme induisant la libération contrôlée de loxycodone du promédicament, de manière à atténuer le clivage enzymatique du promédicament.
